The targeted protein degradation (TPD) market is anticipated to reach USD XXX.X million by 2034 from USD XXX.X million in 2023, at a CAGR of XX.X% during the forecast period 2024-2034.

Drugs that target proteins that were previously deemed "undruggable" due to the lack of optimal binding sites appropriate for small molecule inhibitors can benefit greatly from this strategy. Using the ubiquitin-proteasome system (UPS) or lysosomal degradation pathways to break down undesirable proteins is the fundamental mechanism of TPD.

Request For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/targeted-protein-degradation-market

The majority of it is carried out by forward degraders such as Molecular Glues, Proteolysis Targeting Chimeras (PROTACs), and Lysosome Targeting Chimeras (LYTACs). The market for targeted protein degradation (TPD) has grown significantly in the last several years. The primary causes of the expansion include the rising rates of chronic illness around the world, advancements in proteomics, and significant investments in the research and development of protein degradation technologies.

Growth Drivers:

The growing prevalence of neurological disorders and cancer worldwide is a key factor propelling the market for targeted protein degradation. For example, the International Agency for Research on Cancer (IARC) estimates that 9.7 million people died from cancer and 20 million new cases were diagnosed in 2022. With 2.5 million new cases, or 12.4% of all new cases, lung cancer was the most frequent cancer in the world. Female breast cancer came in second with 2.3 million new cases, or 11.6% of all new cases.

The market for targeted protein degradation has grown significantly due to advancements in biotechnology and medication discovery. Novel strategies, including autophagy-targeting chimeras (AUTACs), lysosome-targeting chimeras (LYTACs), proteolysis-targeting chimeras (PROTACs), and molecular glues, have improved TPD's capacity to specifically eradicate disease-causing proteins.

Targeted Protein Degradation Segmentation:

By Degrader Type:

·         Proteolysis-Targeting Chimeras (PROTACs)

·         Lysosome-Targeting Chimeras (LYTACs)

·         Autophagy-Targeting Chimeras (AUTACs)

·         Selective Estrogen Receptor Degraders (SERDs)

·         Molecular Glues

·         Others

By Indication:

·         Oncology

o   Breast Cancer

o   Multiple Myeloma

o   Others

·         Neurology

·         Others

By End-User:

·        ​​​​​​​Hospitals & Clinics

·         Pharmaceutical & Biotechnology Companies

·         Academic & Research Institutes

·         Others

By Region:

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Key Companies in Targeted Protein Degradation Market:

The research report offers a competitive analysis of prominent companies operating in the global targeted protein degradation market. Some of the leading players profiled in the market research report include:

·         Arvinas

·         AstraZeneca

·         Bristol-Myers Squibb Company

·         C4 Therapeutics, Inc.

·         Ranok Therapeutics Co. Ltd.

·         Nurix Therapeutics, Inc.

·         Foghorn Therapeutics

·         Kymera Therapeutics, Inc.

·         Lycia Therapeutics

·         Kangpu Biopharmaceuticals.

·         Biotheryx, Inc.

·         Other Player’s

For More Information about this Report @ https://www.xresearch.biz/shop/targeted-protein-degradation-market

About Us: -  

xResearch is a market research and consulting organization that uses unique data, expert analysis, and new technologies to create trusted intelligence on industries. Our research is focused on delivering an informed and impartial view on essential market data of industry, and it is primarily driven by an in-depth study covering the following parameters: Market Sizing and Forecasting, Market Segmentation, Competitive Analysis, Strategic Assessment and Business Modelling.

Contact:                                           
Company Name:  xResearch
Contact Person:  James Lin
Email:  sales@xresearch.biz
Phone: +1 718-619-8140

Websites: https://www.xresearch.biz/